Biotech Values

[ThomasS]

MNTA: Combining the 2 tables below (and weighing other intangibles) may give us a clue as to what 2 FoB compounds MNTA/Sandoz might be developing. Dependent, of course on the complexity of the molecule, (which works both for and against MNTA depending on how we view it, i.e., the more complex, the fewer potential market entrants), one might combine mid-term expiration dates with greatest $value to arrive at REMICADE and ENBREL.
Thoughts?